Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

Biomarkers in Medicine

Volumn 7, Issue 4, 2013, Pages 663-671

  Jordheim, Lars Petter ^a,b,c,d   Dumontet, Charles ^a,b,c,d,e  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^d CENTRE LÉON BÉRARD   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

gemcitabine; hENT1; pancreatic cancer; prediction; RRM1

Indexed keywords

3 DEAZANEPLANOCIN A; 3 INDOLEMETHANOL; CO 1 01; CYTIDINE DERIVATIVE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; GEMCITABINE; GEMCITABINE ELAIDATE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMEXON; MESSENGER RNA; NUC 1031; PLATINUM COMPLEX; PRODRUG; RIBONUCLEOTIDE REDUCTASE; SQUALENOYLGEMCITABINE; TRANILAST; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; INOPERABLE CANCER; PANCREAS CANCER; PANCREAS SURGERY; PREDICTIVE VALUE; PROTEIN EXPRESSION; SOLID TUMOR;

ANIMALS; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84881290979     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.48     Document Type: Article

References (60)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012
2. Carmichael J, Fink U, Russell RC et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 73(1), 101-105 (1996
3. Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 12(1), 29-34 (1994
4. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 304(10), 1073-1081 (2010
5. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297(3), 267-277 (2007
6. Jordheim L, Galmarini CM, Dumontet C. Drug resistance to cytotoxic nucleoside analogues. Curr. Drug Targets 4(6), 443-460 (2003
7. Jordheim LP, Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta 1776(2), 138-159 (2007
8. Hung SW, Mody HR, Govindarajan R. Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge. Cancer Lett. 320(2), 138-149 (2012
9. Voutsadakis IA. Molecular predictors of gemcitabine response in pancreatic cancer. World J. Gastrointest. Oncol. 3(11), 153-164 (2011
10. Mackey JR, Yao SY, Smith KM et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J. Natl Cancer Inst. 91(21), 1876-1881 (1999
11. Heinemann V, Xu YZ, Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol. Pharmacol. 38(4), 567-572 (1990
12. Kobayashi H, Murakami Y, Uemura K et al. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. Ann. Surg. 256(2), 288-296 (2012
13. Oguri T, Achiwa H, Muramatsu H et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine- containing chemotherapy in non-small cell lung cancer. Cancer Lett. 256(1), 112-119 (2007
14. Jordheim LP, Seve P, Tredan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 12(7), 693-702 (2011
15. Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 120(6), 1355-1363 (2007
16. Ohhashi S, Ohuchida K, Mizumoto K et al. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res. 28(4B), 2205-2212 (2008
17. Kurata N, Fujita H, Ohuchida K et al. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int. J. Oncol. 39(2), 473-482 (2011
18. Paproski RJ, Young JD, Cass CE. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine. Biochem. Pharmacol. 79(4), 587-595 (2010
19. Perez-Torras S, Garcia-Manteiga J, Mercade E et al. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem. Pharmacol. 76(3), 322-329 (2008
20. Réjiba S, Bigand C, Parmentier C, Hajri A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK:UMK GDEPT and TS/RR siRNA strategies. Neoplasia 11(7), 637-650 (2009
21. Nakano Y, Tanno S, Koizumi K et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 96(3), 457-463 (2007
22. Nakahira S, Nakamori S, Tsujie M et al. Pretreatment with S 1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res. 28(1A), 179-186 (2008
23. Wang H, Word BR, Lyn-Cook BD. Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: The role of human equilibrative nucleoside transporter 1. Anticancer Res. 31(10), 3171-3180 (2011
24. Avan A, Crea F, Paolicchi E et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol. Cancer Ther. 11(8), 1735-1746 (2012
25. Roman NO, Samulitis BK, Wisner L, Landowski TH, Dorr RT. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother. Pharmacol. 67(1), 183-192 (2011
26. Mitsuno M, Kitajima Y, Ohtaka K et al. Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. Int. J. Oncol. 36(2), 341-349 (2010
27. Funel N, Giovannetti E, Pollina LE et al. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Expert Rev. Mol. Diagn. 11(7), 695-701 (2011
28. Kawada N, Uehara H, Katayama K et al. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine. J. Hepatobiliary Pancreat. Sci. 19(6), 717-722 (2012
29. Ashida R, Nakata B, Shigekawa M et al. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. J. Exp. Clin. Cancer Res. 28, 83 (2009
30. Xie H, Jiang W, Jiang J et al. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer 119(1), 173-181 (2013
31. Akita H, Zheng Z, Takeda Y et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28(32), 2903-2909 (2009
32. Marechal R, Bachet JB, Mackey JR et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143(3), 664-674 (2012
33. Nakagawa N, Murakami Y, Uemura K et al. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 153(4), 565-575 (2013
34. Fujita H, Ohuchida K, Mizumoto K et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12(10), 807-817 (2010
35. Sebastiani V, Ricci F, Rubio-Viquiera B et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival. Clin. Cancer Res. 12(8), 2492-2497 (2006
36. Marechal R, Mackey JR, Lai R et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer 116(22), 5200-5206 (2010
37. Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br. J. Haematol. 144(2), 273-275 (2009
38. García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2',2'-difluorodeoxycytidine-induced cytotoxicity. Clin. Cancer Res. 9(13), 5000-5008 (2003
39. Marechal R, Mackey JR, Lai R et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15(8), 2913-2919 (2009
40. Réjiba S, Reddy LH, Bigand C, Parmentier C, Couvreur P, Hajri A. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 7(6), 841-849 (2011
41. Bildstein L, Pili B, Marsaud V et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. Eur. J. Pharm. Biopharm. 79(3), 612-620 (2011
42. Jordheim LP, Cros E, Gouy MH et al. Characterization of a gemcitabine-resistant murine leukemic cell line: Reversion of in vitro resistance by a mononucleotide prodrug. Clin. Cancer Res. 10(16), 5614-5621 (2004
43. Gouy MH, Jordheim LP, Lefebvre I et al. Special feature of mixed phosphotriester derivatives of cytarabine. Bioorg. Med. Chem. 17(17), 6340-6347 (2009
44. Wu W, Sigmond J, Peters GJ, Borch RF. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J. Med. Chem. 50(15), 3743-3746 (2007
45. Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br. J. Surg. 98(8), 1041-1055 (2011
46. Winter JM, Yeo CJ, Brody Jr. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J. Surg. Oncol. 107(1), 15-22 (2013
47. Simon G, Sharma A, Li X et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 25(19), 2741-2746 (2007
48. Simon GR, Schell MJ, Begum M et al. Preliminary indication of survival benefit from ERCC1 and RRM1-Tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer 118(9), 2525-2531 (2012
49. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364(19), 1817-1825 (2011
50. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin. Cancer Res. 18(16), 4266-4276 (2012
51. Perez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142(5), 1079-1092 (2012
52. Spratlin J, Sangha R, Glubrecht D et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-Treated pancreas adenocarcinoma. Clin. Cancer Res. 10(20), 6956-6961 (2004
53. Farrell JJ, Elsaleh H, Garcia M et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1), 187-195 (2009
54. Morinaga S, Nakamura Y, Watanabe T et al. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann. Surg. Oncol. 19(Suppl. 3), S558-S564 (2012
55. Murata Y, Hamada T, Kishiwada M et al. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy. J. Hepatobiliary Pancreat. Sci. 19(4), 413-425 (2012
56. Kondo N, Murakami Y, Uemura K et al. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S 1 chemotherapy after surgical resection. Ann. Surg. Oncol. 19(Suppl. 3), S646-S655 (2012
57. Valsecchi ME, Holdbrook T, Leiby BE et al. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer 12, 104 (2012
58. Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66(7), 3928-3935 (2006
59. Kim R, Tan A, Lai KK et al. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 117(14), 3126-3134 (2011
60. Fisher SB, Patel SH, Bagci P et al. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment. Cancer 119(2), 445-453 (2013